Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Urinary Tract Infection

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 45 articles: HTML format

Single Articles

October 2025
1. LARKIN C, Valappil SP, Palanisamy N
   Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis.
   J Antimicrob Chemother. 2025;80:2609-2621.
   PubMed     Abstract available
   
   
   
2. KOENIG C, Yi F, Nicolau DP, Asempa TE, et al
   In vivo activity of ceftibuten-ledaborbactam oral combination against serine-beta-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model.
   J Antimicrob Chemother. 2025;80:2714-2718.
   PubMed     Abstract available
   
   
   September 2025
3. IACHKINE J, Alexandre K, Marlat C, Briant A, et al
   Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study.
   J Antimicrob Chemother. 2025 Sep 30:dkaf370. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. ELADAWY M, Heslop N, Negus D, Thomas JC, et al
   Phenotype-genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt.
   J Antimicrob Chemother. 2025 Sep 23:dkaf352. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2025
5. STURM PDJ, Schulin T
   Rapid susceptibility testing on urine for antimicrobial stewardship in general practice.
   J Antimicrob Chemother. 2025;80:1926-1932.
   PubMed     Abstract available
   
   
   
6. KOONG J, Hall RM, Hamidian M
   Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875.
   J Antimicrob Chemother. 2025;80:1988-1992.
   PubMed     Abstract available
   
   
   June 2025
7. HONDA T, Vazquez-Montes MDLA, Fanshawe TR, Stoesser N, et al
   The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time.
   J Antimicrob Chemother. 2025 Jun 24:dkaf194. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. HANDAL N, Kaspersen H, Mo SS, Cabanel N, et al
   A comparative study of the molecular characteristics of human uropathogenic Escherichia coli collected from two hospitals in Norway and France in 2019.
   J Antimicrob Chemother. 2025;80:1707-1715.
   PubMed     Abstract available
   
   
   February 2025
9. HUNTER CJ, Marhoffer EA, Holleck JL, Ein Alshaeba S, et al
   Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.
   J Antimicrob Chemother. 2025;80:322-333.
   PubMed     Abstract available
   
   
   December 2024
10. ZOHAR I, Ben David D, Schwartz O, Pomerantz A, et al
    Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality.
    J Antimicrob Chemother. 2024;79:3204-3209.
    PubMed     Abstract available
    
    
    November 2024
11. LEROY AG, Lemenand O, Thibaut S, Coeffic T, et al
    Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home-acquired urinary tract infections.
    J Antimicrob Chemother. 2024 Nov 29:dkae431. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. ABBOTT IJ, Anderson CRB, van Gorp E, Wallis SC, et al
    Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model.
    J Antimicrob Chemother. 2024 Nov 29:dkae424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. HERNANDEZ-LOZANO I, Aranzana-Climent V, Cao S, Matias C, et al
    Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections.
    J Antimicrob Chemother. 2024 Nov 16:dkae409. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
14. MASSIP C, Feletti L, Chagneau CV, Dumont Y, et al
    Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.
    J Antimicrob Chemother. 2024;79:2645-2652.
    PubMed     Abstract available
    
    
    September 2024
15. DIZI ISIK A, Akkoc G, Ergenc Z, Yilmaz S, et al
    The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience.
    J Antimicrob Chemother. 2024;79:2179-2185.
    PubMed     Abstract available
    
    
    August 2024
16. MEIJS AP, Chaname-Pinedo LE, Deng H, Veldman KT, et al
    Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009-2020.
    J Antimicrob Chemother. 2024 Aug 2:dkae268. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
17. WIJNANT GJ, Ngougni Pokem P, Coessens M, Cottone E, et al
    Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections.
    J Antimicrob Chemother. 2024 Jul 10:dkae215. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
18. TUINTE RAM, van Zanten MD, Takamura T, Schoffelen T, et al
    Follow-up of patients with urinary tract infections discharged from the emergency department: a mixed methods study.
    J Antimicrob Chemother. 2024 May 31:dkae169. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. MENENDEZ ALVARADO LR, Margulis Landayan A, Williams KN, Frederick CM, et al
    Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections.
    J Antimicrob Chemother. 2024 May 8:dkae135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. RECH MA, Faine BA, Gross AE, Vakkalanka P, et al
    Empirical antimicrobial prescribing for pyelonephritis in patients discharged from 15 US Emergency Departments: an opportunity for improvement.
    J Antimicrob Chemother. 2024;79:1038-1044.
    PubMed     Abstract available
    
    
    March 2024
21. HELTVEIT-OLSEN SR, Gopinathan U, Blix HS, Elstrom P, et al
    Effect of methenamine hippurate shortage on antibiotic prescribing for urinary tract infections in Norway-an interrupted time series analysis.
    J Antimicrob Chemother. 2024 Mar 28:dkae078. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
22. BAYART J, Drouet J, Peycelon M, Mariani P, et al
    Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
    J Antimicrob Chemother. 2024 Feb 27:dkae053. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. PIAZZOLLA HRW, Modin F, Halkjaer SI, Petersen AM, et al
    The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies.
    J Antimicrob Chemother. 2024;79:241-254.
    PubMed     Abstract available
    
    
    January 2024
24. MONTELIN H, Camporeale A, Hallgren A, Angelin M, et al
    Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.
    J Antimicrob Chemother. 2024 Jan 10:dkad402. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. ARYEE A, Rockenschaub P, Robson J, Ahmed Z, et al
    Assessing the impact of discordant antibiotic treatment on adverse outcomes in community-onset UTI: a retrospective cohort study.
    J Antimicrob Chemother. 2024;79:134-142.
    PubMed     Abstract available
    
    
    December 2023
26. HATTORI Y, Tahara S, Aso S, Makito K, et al
    Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan.
    J Antimicrob Chemother. 2023;78:2909-2914.
    PubMed     Abstract available
    
    
    November 2023
27. KASHOURIS E, Joseph A, Lewis T
    Nitrofurantoin: what is the evidence for current UK guidance?
    J Antimicrob Chemother. 2023;78:2605-2611.
    PubMed     Abstract available
    
    
    
28. TORRES A, Wible M, Tawadrous M, Irani P, et al
    Efficacy and safety of ceftazidime/avibactam in patients with infections caused by beta-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
    J Antimicrob Chemother. 2023;78:2672-2682.
    PubMed     Abstract available
    
    
    September 2023
29. NGUYEN HM, Flerchinger S, Smith JR, Felcher AH, et al
    Diagnostic and antibiotic stewardship lessons: an outpatient assessment of symptomatic reflex urinalysis ordering accuracy using an electronic best-practice alert.
    J Antimicrob Chemother. 2023;78:2283-2290.
    PubMed     Abstract available
    
    
    August 2023
30. CARTER C, Hutchison A, Rudder S, Trotter E, et al
    Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK.
    J Antimicrob Chemother. 2023;78:2028-2036.
    PubMed     Abstract available
    
    
    July 2023
31. FANSHAWE TR, Judge RK, Mort S, Butler CC, et al
    Evidence-based appraisal of two guidelines for the diagnosis of suspected, uncomplicated urinary tract infections in primary care: a diagnostic accuracy validation study.
    J Antimicrob Chemother. 2023 Jul 4:dkad212. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
32. SOJO-DORADO J, Lopez-Hernandez I, Hernandez-Torres A, Retamar-Gentil P, et al
    Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
    J Antimicrob Chemother. 2023 Jun 1:dkad147. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. MAHER JM, Huband MD, Blankers CG, Puttagunta S, et al
    In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
    J Antimicrob Chemother. 2023;78:1406-1414.
    PubMed     Abstract available
    
    
    May 2023
34. PURCELL R, Yeoh D, Bowen A, Britton PN, et al
    A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents.
    J Antimicrob Chemother. 2023 May 16:dkad131. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
35. WATKINS RR, Thapaliya D, Lemonovich TL, Bonomo RA, et al
    Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea.
    J Antimicrob Chemother. 2023 Mar 8:dkad060. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
36. VALLEE M, Harding C, Hall J, Aldridge PD, et al
    Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
    J Antimicrob Chemother. 2023;78:373-379.
    PubMed     Abstract available
    
    
    
37. ABBOTT IJ, van Gorp E, Cottingham H, Macesic N, et al
    Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    J Antimicrob Chemother. 2023;78:397-410.
    PubMed     Abstract available
    
    
    January 2023
38. CHEN L, Hua J, Hong SJ, Yuan CY, et al
    Comparison of the relative efficacy of beta-lactam/beta-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational coh
    J Antimicrob Chemother. 2023 Jan 24:dkac448. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
39. FRIMODT-MOLLER N, Simonsen GS, Larsen AR, Kahlmeter G, et al
    Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption.
    J Antimicrob Chemother. 2022;78:289-295.
    PubMed     Abstract available
    
    
    November 2022
40. GUO S, Li X, Li Y, Tong H, et al
    Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
    J Antimicrob Chemother. 2022 Nov 4. pii: 6795394. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2022
41. WALKTY AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, et al
    In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).
    J Antimicrob Chemother. 2022 Sep 30. pii: 6731707. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
42. EMERAUD C, Godmer A, Girlich D, Vanparis O, et al
    Activity of mecillinam against carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2022 Jul 11. pii: 6639593. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
43. ABBOTT IJ, van Gorp E, Wyres KL, Wallis SC, et al
    Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
    J Antimicrob Chemother. 2022;77:1324-1333.
    PubMed     Abstract available
    
    
    
44. FUCHS F, Becerra-Aparicio F, Xanthopoulou K, Seifert H, et al
    In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
    J Antimicrob Chemother. 2022 Apr 12. pii: 6566767. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2022
45. NEVILLE LF, Shalit I, Warn PA, Rendell JT, et al
    Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
    J Antimicrob Chemother. 2022 Mar 1. pii: 6539950. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Urinary Tract Infection is free of charge.